Physician profile
Maya Dema
NPI 1477279255
$2,079.63
in general payments reported to CMS, 2019-2025
16 companies · $192 in 2025
The $192 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $50.17 · 2023: $996 · 2024: $842 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,029.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $630.50 | 2023-2024 | |
| Pfizer INC. | $443.36 | 2023-2025 | |
| Eisai INC. | $254.34 | 2023-2024 | |
| Lilly USA, LLC | $133.78 | 2023-2025 | Emgality, Kisunla |
| Novartis Pharmaceuticals Corporation | $118.95 | 2022-2025 | |
| Tanabe Pharma America, INC. | $111.56 | 2023-2025 | Radicava |
| Mallinckrodt Hospital Products INC. | $81.17 | 2022-2024 | Acthar |
| Teva Pharmaceuticals USA, INC. | $75.84 | 2023 | Austedo, Austedo Xr |
| Genentech USA, INC. | $62.28 | 2024-2025 | Ocrevus Zunovo |
| Ucb, INC. | $43.04 | 2023-2024 | Rystiggo, Briviact |
| Kyowa Kirin, INC. | $29.94 | 2024 | Nourianz |
| Acadia Pharmaceuticals INC | $26.82 | 2024 | Nuplazid |
| Lundbeck LLC | $19.81 | 2025 | Vyepti |
| Otsuka America Pharmaceutical, INC. | $19.72 | 2024 | Rexulti |
| Amneal Pharmaceuticals LLC | $16.63 | 2024 | Ongentys |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $11.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maya Dema listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.